机译:艾尔赤虫和蓖麻油蛋白在临床试验外部处理的复发/难治性慢性淋巴细胞白血病的疗效。 关于Gimema工作组的报告
Univ Ferrara Dept Med Sci Hematol Sect Cona Ferrara Italy;
Univ Ferrara Dept Med Sci Hematol Sect Cona Ferrara Italy;
GIMEMA Fdn Rome Italy;
GIMEMA Fdn Rome Italy;
Univ Padua Dept Med Hematol &
Clin Immunol Unit Padua Italy;
Fdn IRCCS Ca Granda Osped Maggiore Policlin Milan Ematol Milan Italy;
ASST Grande Osped Metropolitano Niguarda Niguarda Canc Ctr Hematol Milan Italy;
Osped Ca Foncello Hematol Treviso Italy;
Cardarelli Hosp Hematol Naples Italy;
Univ Torino Dept Mol Biotechnol &
Hlth Sci Turin Italy;
Fdn IRCCS Ist Nazl Tumori Div Hematol Milan Italy;
Univ Piemonte Orientale Dept Translat Med Div Hematol Novara Italy;
Osped Oncol A Businco Hematol &
Stem Cell Transplantat Unit ARNAS G Brotzu Cagliari Italy;
Fdn IRCCS Policlin San Matteo Div Hematol Pavia Italy;
Rovigo Gen Hosp Hematol Unit Rovigo Italy;
Osped S Maria Misericordia Dept Med &
Surg Inst Hematol Perugia Italy;
Osped Civile SS Antonio &
Biagio Hematol Div Dipartimento Internist Struttura Complessa Ematol;
Osped Infermi Hematol Rimini Italy;
Univ Verona Dept Med Sect Hematol Verona Italy;
Fdn Policlin Univ Gemelli Roma IRCCS Rome Italy;
Univ Modena &
Reggio Emilia Dept Med &
Surg Sci Sect Hematol Modena Italy;
Cardinal Massaia Hosp Oncol Unit Asti Italy;
Sapienza Univ Dept Translat &
Precis Med Hematol Rome Italy;
GIMEMA Fdn Rome Italy;
GIMEMA Fdn Rome Italy;
AO Cosenza Hematol Unit Dept Oncohematol Cosenza Italy;
ASST Grande Osped Metropolitano Niguarda Niguarda Canc Ctr Hematol Milan Italy;
Sapienza Univ Dept Translat &
Precis Med Hematol Rome Italy;
Univ Ferrara Dept Med Sci Hematol Sect Cona Ferrara Italy;
chronic lymphocytic leukemia; idelalisib; realamp; 8208; world evidence;
机译:艾尔赤素蛋白加里妥昔单抗和伊布勒替尼在复发/难治性慢性淋巴细胞白血病中的可比疗效:一种回顾性案例与波兰成人白血病组(Palg)的研究匹配研究
机译:Ascend第3阶段3 acalabrutinib与调查患者选择Rituximab Plus Idelalisib(IDR)或Bendamustine(Br)的复发/难治性(R / R)慢性淋巴细胞白血病(CLL)的选择
机译:通过调查仪选择在复发/难治度(R / R)慢性淋巴细胞白血病中的研究acalabrutinib vs rituximab vs idelalisib(IDR)或弯曲蛋白(Br):第3阶段提升研究
机译:面向3D蛋白质结构的慢性淋巴细胞白血病患者临床关系的发现
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:依达拉西布联合利妥昔单抗或苯达莫司汀或两者联合用于复发/难治性慢性淋巴细胞白血病患者
机译:Idelalisib与Rituximab或Bendamustine组合或患有复发/难治性慢性淋巴细胞白血病的患者
机译:慢性粒细胞白血病在两个费城染色体的淋巴细胞爆炸危机中呈现:病例报告